Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/92543
DC Field | Value | Language |
---|---|---|
dc.contributor | School of Optometry | en_US |
dc.contributor | School of Optometry | en_US |
dc.contributor | Research Centre for SHARP Vision | en_US |
dc.creator | Fu, J | en_US |
dc.creator | Wang, Y | en_US |
dc.creator | Li, H | en_US |
dc.creator | Zhou, H | en_US |
dc.creator | Song, H | en_US |
dc.creator | Sun, M | en_US |
dc.creator | Xu, Q | en_US |
dc.creator | Tan, S | en_US |
dc.creator | Wei, S | en_US |
dc.date.accessioned | 2022-04-26T05:59:54Z | - |
dc.date.available | 2022-04-26T05:59:54Z | - |
dc.identifier.issn | 2193-8253 | en_US |
dc.identifier.uri | http://hdl.handle.net/10397/92543 | - |
dc.language.iso | en | en_US |
dc.publisher | Springer Healthcare Communications Ltd. | en_US |
dc.rights | © The Author(s) 2022 | en_US |
dc.rights | This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. | en_US |
dc.rights | The following publication Fu, J., Wang, Y., Li, H. et al. Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study. Neurol Ther 11, 797–813 (2022) is available https://doi.org/10.1007/s40120-022-00344-w | en_US |
dc.subject | Acute optic neuritis | en_US |
dc.subject | Antibody | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Plasma exchange | en_US |
dc.title | Efficacy of plasma exchange treatment for demyelinating optic neuritis associated with various serum antibodies : a prospective cohort study | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 797 | en_US |
dc.identifier.epage | 813 | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.doi | 10.1007/s40120-022-00344-w | en_US |
dcterms.abstract | Introduction: To evaluate the value of plasma exchange (PE) for patients with three subtypes of demyelinating optic neuritis (ON): aquaporin-4 (AQP4) antibody-positive ON (AQP4-ON), myelin oligodendrocyte glycoprotein (MOG) antibody-positive ON (MOG-ON), and AQP4 and MOG double-antibody-seronegative ON (D-ON). | en_US |
dcterms.abstract | Methods: A single-center prospective study compared the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) at most severe onset, 1 day before intravenous high-dose methylprednisolone (IVMP) treatment, 1 day before PE treatment, after five-cycles of PE therapy, and at 1-, 3-, and 6-month follow-up visits. The proportions of eyes in each visual outcome category were also compared. Logistic regression and a receiver operating characteristic curve were used to analyze predicted factors for VA improvement. | en_US |
dcterms.abstract | Results: A total of 124 ON attacks of 122 patients were included. No significant differences were found in BCVA (P = 0.659) before and after PE therapy for 22 D-ON attacks, but VA improved in two of six MOG-ON patients. In 95 AQP4-ON patients suffering 96 attacks, the mean logMAR BCVA markedly improved and was steadily maintained after five-cycles of PE treatments (adjusted P < 0.001), with VA exhibiting a significantly increasing trend (adjusted P = 0.001) after PE treatment. The combination of the number of previous ON episodes and the time window to PE treatment showed accuracy of 74.7% for predicting an improvement in BCVA score ≥ 2 levels. In addition, a combination of logMAR VA before PE and the time window to PE treatment resulted in 83.4% accuracy in predicting whether VA would regain 1.0 logMAR. | en_US |
dcterms.abstract | Conclusion: PE therapy effectively improves visual outcomes for AQP4-ON patients, but offers limited value for D-ON patients. Early initiation greatly increases likelihood of achieving VA improvement. | en_US |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Neurology and therapy, June 2022, v. 11, no. 2, p. 797-813 | en_US |
dcterms.isPartOf | Neurology and therapy | en_US |
dcterms.issued | 2022-06 | - |
dc.identifier.scopus | 2-s2.0-85127690064 | - |
dc.identifier.eissn | 2193-6536 | en_US |
dc.description.validate | 202204 bchy | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | a1347-n04 | - |
dc.description.fundingSource | Others | en_US |
dc.description.fundingText | National Key Research and Development Program (project code: 2018YFE0113900 to S.W.); the National Natural Science Foundation of China (project code: 81870662 to S.W. and project code: 81800822 to. S.T.) | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s40120-022-00344-w.pdf | 1.18 MB | Adobe PDF | View/Open |
Page views
62
Last Week
2
2
Last month
Citations as of May 12, 2024
Downloads
11
Citations as of May 12, 2024
SCOPUSTM
Citations
3
Citations as of May 17, 2024
WEB OF SCIENCETM
Citations
2
Citations as of May 16, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.